# NNIT


Copenhagen Winter Seminar2015 Danske Bank 3 December 2015



### Forward looking statements

This presentation contains forward-looking statements. Words such as 'believe', 'expect', 'may', 'will', 'plan', 'strategy', 'prospect', 'foresee', 'estimate', 'project', 'anticipate', 'can', 'intend', 'outlook', 'guidance', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Statements regarding the future are subject to risks and uncertainties that may result in considerable deviations from the outlook set forth. Furthermore, some of these expectations are based on assumptions regarding future events which may prove incorrect.

### NNIT – who we are



Revenue 2014 (contribution to total - %)

**DKK 743m** 

(31%)


application management

**DKK 1,667m** (69%)

consulting, support services

Note

### The Key Pillars of Our Growth Strategy



## Life Sciences

Our core




# Generalist IT Providers are Not Tailored to a Complex Environment

#### **Complexity of GxP**

- Operation of GxP environments requires a high degree of industry and business understanding, as well as audit readiness
- GxP compliance includes requirements for:
  - Secure logging
  - Auditing
  - Keeping archives
  - Accountability
  - Non-repudiation
  - Stringent record-keeping requirements and traceability
  - Litigation and regulation support

#### Standard Practice to use the V-Model when Building Solutions within Life Sciences



nn

### Strong Expertise in Life Sciences and focused strategy

NNIT Delivers Value Added and Leading-edge Solutions tailored to Well- Recognized Pharmaceutical Groups by focusing...



Pharma value chain

Drug development

Quality management

**Regulatory Affairs** 

Regulatory driven



Selected companies

**Pharmaceutical** 

#### **Geographical Focus**

- Tier 1 expert knowledge
- Tier 2 Scale fit


Supply Chain

- US east cost
- Swiss pharma area (Zurich-Basel)
- Germany (Frankfurt area)
- UK (South England)
- China (mainland)




### Regulatory environment Drives IT investments

#### **Expected Regulatory Changes**



### Deep Array of Differentiated Solutions



# NNIT is ready

ISO IDMP	<ul> <li>NNIT is industry leading IDMP service provider</li> <li>Industry will start to move to next phase: Implementation</li> <li>NNIT have productized FDA's substance database (GiNAS) and are exploring the market for GiNAS as a Service</li> </ul>
Serilization	<ul> <li>AT&amp;T is SAP's solution for Serialization of the Pharmaceutical industry and was released September 15, 2015</li> <li>NNIT is qualified SAP AT&amp;T implementation partner and have two Proof of Concept ongoing</li> </ul>
ICE	<ul> <li>NNIT ICE offering is addressing the FDA - Regulatory Submissions in Electronic Format.</li> <li>NNIT ICE is the out-of-the box full implementation, support and hosting of a Clinical Information Environment</li> </ul>
10	


### Offering GxP Cloud Dedicated to Life Sciences

#### Current GxP Cloud, pre-validated – private



- Offers the traditional cloud computing benefits such as scalability, elasticity, pay-per-use, monitoring, and availability, and adds:
  - Full data control with data and applications stored in a secure environment
  - Security through virtual network separation of customer applications and data
  - Compliance with qualified processes and components through organizational and platform audit readiness
  - Agile and fast deployment on a prevalidated platform
  - Lower costs through automation, standardization and shared platforms

#### Future GxP Cloud, pre-validated – Hybrid: Private and Public Roadmap




- \* A prerequisite is that NNIT receives information about processes used to operate and maintain External Fabric
- Offers the same as the existing GxP Cloud however based on new technology which allows in future for the opportunity to use NNIT or third party Cloud provider
  - Third party provider in so far that NNIT receives information about processes used to operate and maintain

### Life sciences in numbers

		9 Month			
DKK million	2015 (reported)	2015 (constant)	2014	Pct Change (reported)	Pct Change (constant)
Revenue	1,170.3	1,155.6	1,084.3	7.9%	6.6%
hereof Novo Nordisk	Group 923.9	915.9	882.6	4.7%	3.8%
, Hereof other Life Scie	ences 246.5	239.7	201.7	22.2%	18.8%

Clients (in 2015): 34 – excl. China
 Clients in China (in 2015): 10



### Investor contact information

#### **Upcoming events**

3 December 2015:	Presentation at Danske Bank Markets' Copenhagen Winter Seminar 7
7 January 2015:	Presentation at SEB Nordic Seminar, Copenhagen
27 January 2015:	Full year 2015 reporting

#### **Investor contact**

NNIT A/S Østmarken 3A 2860 Søborg Denmark

Jesper Wagener +45 3075 5392 jvwa@nnit.com

# Five phases towards IDMP compliance

PHASE I: INITIATE	PHASE II: ANALYSE	PHASE III: EXECUTE	PHASE IV: EXECUTE	PHASE V: REALISE			
IMPACT ASSESSMENT • Identification of source fields and systems • GAP analysis • Impact of controlled vocabularies • Management Reports • Business Case Development	BUSINESS PREPARATION • Field risk analysis • Preparation of source systems • Action plan for data GAP • Enterprise architecture & governance • Implementation Strategy	SOFTWARE & VENDOR SELECTION • URS • Assessment of vendor and solutions	<ul> <li>APPLICATION SETUP AND INTERFACING</li> <li>Software accelerator for quick setup</li> <li>Setup of interfaces</li> <li>Alignment / cleaning of source systems</li> <li>Submit data</li> </ul>	HOSTING AND SUPPORT • Hosting • Support • Application development			
BUSINESS PROCESSES & SOPS							

**PROJECT SUPPORT & OCM** 

